Effects of different administration methods of Piperacillin and Tazobactam on pharmacokinetics and pharmacodynamics in critically ill patients with pulmonary infection

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052546

Enrollment

Unknown

Registered

2021-10-30

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary infection in critically ill patients

Interventions

experimental group:Piperacillin/tazobactam 4.5g for injection was added with 0.9% sodium chloride injection to form 100 ml, and the infusion rate was controlled through an infusion pump (infusion rate

control group:Piperacillin/tazobactam 4.5g for injection was added into 0.9% sodium chloride injection 100ml intravenously at a constant rate for 1 hour, once every 8 hours

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Critical patients admitted to the ICU.

Exclusion criteria

Exclusion criteria: Those who had blood disease or immune system disease, mental system disease, malignant tumor and those who had used corticosteroid or immunosuppressive drugs within 6 months.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics, pharmacodynamics;	—

Secondary

Measure	Time frame
C-reactive protein;Procalcitonin;White blood cells;	—

Countries

China

Contacts

Public ContactZhang Xuemin

Shanghai Fifth People’s Hospital

zhangxm922@126.com+86 18916073209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026